KEYNOTE-859

NCT03675737 📎

Regimen

Experimental
pembrolizumab 200 mg Q3W + FP or CAPOX
Control
placebo + FP or CAPOX

Population

HER2-negative advanced gastric/GEJ adenocarcinoma as first-line therapy

Key finding

ITT mOS 12.9 vs 11.5 mo (HR 0.78, 95% CI 0.70-0.87, p<0.0001); CPS>=10 HR 0.65; mPFS 6.9 vs 5.6 mo (HR 0.76); ORR 51.3% vs 42.0%

Source: PMID 37875143

Timeline

    Guideline citations

    • NCCN GASTRIC (p.45)
    • CSCO GASTRIC 2025 (p.80)⚠️ OCR source